SCHEMBL3275484

SCHEMBL3275484

O=C(O)Cc1c(C(=O)O)n(Cc2csc3ccc(F)cc23)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 8/20 0.53
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.47
CMA1 P23946 1/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.43
ALOX15 P16050 1/20 0.42
MAPT P10636 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3275397 0.93 PTGDR2 (0.45) FOLH1KMT2AMEN1CMA1PTGDR2
SCHEMBL3274934 0.89 KMT2A (0.43) FOLH1KMT2APOLBMEN1CMA1
SCHEMBL27749629 0.87 POLB (0.52) FOLH1KMT2APOLBMEN1CMA1
SCHEMBL3276339 0.84 POLB (0.48) FOLH1KMT2APOLBMEN1MAPT
SCHEMBL3276068 0.84 POLB (0.48) FOLH1KMT2APOLBMEN1MAPT
SCHEMBL15512655 0.84 KMT2A (0.68) KMT2APOLBMEN1CMA1MAPT
SCHEMBL3275754 0.82 POLB (0.52) KMT2APOLBMEN1MAPT
SCHEMBL3275759 0.82 POLB (0.43) FOLH1KMT2APOLBMEN1CMA1
SCHEMBL3279513 0.82 MTNR1A (0.42) KMT2APOLBMEN1PTGDR2MAPT
SCHEMBL3281216 0.81 FOLH1 (0.57) FOLH1KMT2APOLBMEN1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 FOLH1 125/4885KMT2A 3786/4885POLB 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.